HIV/HCV合并感染者使用药物者中,ledipasvir/sofosbuvir治疗不依从未能预测持续病毒学应答
这项随机对照试验纳入144名HIV/HCV合并感染且患有物质使用障碍的参与者,其中110人启动12周ledipasvir/sofosbuvir治疗。尽管存在不完美依从和物质使用障碍,治疗坚持仍带来高持续病毒学应答率。
要点
- HIV/HCV合并感染且物质使用障碍者中,坚持治疗者95%达到持续病毒学应答。
- 低依从性与磷脂酰乙醇提示的中重度饮酒相关(相对风险=2.77;95%置信区间1.50-5.12)。
核心结论
- 在HIV/HCV合并感染且患有物质使用障碍的参与者中,治疗坚持导致高持续病毒学应答率,尽管依从性不完美。
研究设计与样本
- 随机对照试验,144名HIV/HCV合并感染且患有物质使用障碍的参与者中110人启动12周ledipasvir/sofosbuvir治疗,随机分配至常规护理、同伴导师或现金激励三种条件之一。
主要发现
- 启动治疗后大多数参与者坚持治疗(n=105),其中95%(n=100)达到持续病毒学应答。
- 高依从性(服用≥90%剂量)者占72%(n=76),低依从性(服用<90%剂量)者占28%。
- 低依从性与磷脂酰乙醇提示的中重度饮酒相关(相对风险=2.77;95%置信区间1.50-5.12)。
- 三分之一的参与者(34%)通过磷脂酰乙醇(≥50 ng/mL)判定为中重度饮酒,44%入组时尿液毒理学可卡因或海洛因阳性。
临床怎么用
- 对于HIV/HCV合并感染且有物质使用障碍者,启动ledipasvir/sofosbuvir治疗后应鼓励坚持治疗,即使依从性不完美也可能获得高持续病毒学应答率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Eliminating hepatitis C virus (HCV) will require effective treatment delivery to persons with substance use disorders (SUDs). We evaluated the relationship between ledipasvir/sofosbuvir treatment persistence (receiving 84 tablets), adherence, and sustained virologic response (SVR) in persons with human immunodeficiency virus (HIV)/HCV coinfection. METHODS: Of the 144 participants with HIV/HCV and SUDs, 110 initiated a 12-week treatment course under 1 of 3 conditions (usual care, peer mentors, and cash incentives). We used self-report, pharmacy pill counts, and expected date of refill to examine adherence. Persistent participants were categorized as high adherence (taking ≥90% of doses) or low adherence (taking <90% of doses). RESULTS: Most participants persisted on treatment after initiation (n = 105), with 95% (n = 100) achieving SVR. One third (34%) of participants had moderate/heavy alcohol use by the biomarker phosphatidylethanol ([Peth] ≥50 ng/mL), and 44% had urine toxicology positive for cocaine or heroin at enrollment. The proportion of persons with high adherence was 72% (n = 76), and the proportion of persons with low adherence was 28%. Although low adherence was associated with moderate/heavy alcohol use by PEth (relative risk = 2.77; 95% confidence interval, 1.50-5.12), SVR did not vary according to adherence (P = .702), and most participants (97%) with low adherence achieved SVR. CONCLUSIONS: Treatment persistence led to high SVR rates among persons with HIV/HCV, despite imperfect adherence and SUDs.
引用
- Ward KM, Falade-Nwulia O, Moon J, et al. Nonadherence to Ledipasvir/Sofosbuvir Did Not Predict Sustained Virologic Response in a Randomized Controlled Trial of Human Immunodeficiency Virus/Hepatitis C Virus Coinfected Persons Who Use Drugs. J Infect Dis. 2022. PMID: 34543417. doi:10.1093/infdis/jiab477
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。